Gary P. Pisano
Harry E. Figgie, Jr. Professor of Business Administration
Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School. He has been on the Harvard faculty for 23 years. During this time, he has taught MBA and executive level courses on technology and operations management, operations strategy, competitive strategy, product development, and the management of innovation. Professor Pisano's research has examined technology strategy, the management of innovation, organizational learning, outsourcing, and the management of intellectual property. His research, teaching, and consulting on these issues span a range of science and technology based industries including aerospace, biotechnology and pharmaceuticals, health care, computers, software, telecommunications, and semiconductors.
Pisano is the author of over 70 articles and case studies. His "Restoring American Competitiveness" (co-authored with Willy Shih) won the McKinsey Award for best article published in Harvard Business Review in 2009. He is also co-author of the award winning article, "Dynamic Capabilities and Strategic Management" (Strategic Management Journal, 1997), the most-cited publication in economics and business from 1995-2005. His article "How to Capture Value from Innovation: Shaping Intellectual Property and Industry Architecture" (California Management Review) was a finalist for the 2008 Accenture Award. He has also written case studies on such companies as Amazon, BMW, ITT-Automotive, IBM, Intel, Jet Blue, Merck, Eli Lilly, Vertex Pharmaceuticals, Teradyne, and Flextronics. He is the author of six books including The Development Factory; Operations, Strategy, and Technology (with co-authors Robert Hayes, David Upton, and Steve Wheelwright); and Science Business: The Promise, The Reality and The Future of Biotech. Professor Pisano is currently writing a book on the challenges facing U.S. competitiveness in high-technology industries. Professor Pisano has served as an advisor to senior executives at leading companies in the United States and Europe in the aerospace, biotechnology, pharmaceutical, medical device, computer, software, electronics, and financial services industries. In addition, Pisano has served on the Board of Directors and Advisory Boards of a number of start-up companies. He speaks widely at industry conferences and to senior executive audiences. Professor Pisano holds a Ph.D. from the University of California, Berkeley and B.A. in economics from Yale University. For more information on Professor Pisano's research and activities, please go to http://www.gpisano.com.
Restoring American Competitiveness
For decades, U.S. companies have been outsourcing manufacturing in the belief that it held no competitive advantage. That’s been a disaster, maintain Harvard professors Pisano and Shih, because today’s low-value manufacturing operations hold the seeds of tomorrow’s innovative new products.
What those companies have been ceding is the country’s industrial commons—that is, the collective operational capabilities that underpin new product and process development in the U.S. industrial sector. As a result, America has lost not only the ability to develop and manufacture high-tech products like televisions, memory chips, and laptops but also the expertise to produce emerging hot products like the Kindle e-reader, high-end servers, solar panels, and the batteries that will power the next generation of automobiles.
To rebuild the commons and restore its wealth-generating machine will require government and industry in the United States to make two drastic changes. Read the full article
Science Business: The Promise, the Reality, and the Future of Biotech
Why has the biotechnology industry failed to perform up to expectations despite all its promise? In Science Business, Professor Gary Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech's problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policymakers seeking ways to improve the industry's performance. The payoff? Valuable improvements in health care and a shinier future for human well-being.
Named Best Biotech Book in 2007 by strategy+business.